China, Aug. 19 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Iparomlimab and Tuvonralimab in Combination with Trastuzumab Rezetecan for the Treatment of HER2-low Advanced Breast Cancer: A Single-arm, Multicenter, Phase II Clinical Study'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600130268
Registration Time: 2026/08/18
Type: Interventional study
Primary Sponsor: Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital ＆Institute)
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=305646
Published by HT Digital Content Services with permission from Health Daily Digest....